This market-focused realignment will make it even easier for customers to do business with Aptargroup through a wider and innovative range of products and services available under the new Aptar Pharma brand.

read more

This market-focused realignment will make it even easier for customers to do business with Aptargroup through a wider and innovative range of products and services available under the new Aptar Pharma brand.

 

 

A market-focused realignment

 

For many years Pfeiffer and Valois have been members of Aptargroup, a family of companies who, together, are leaders in the consumer dispensing and drug delivery systems industry.

 

Aptargroup recently announced a strategic realignment of its businesses under three market-focused business segments: Aptar Beauty + Home, Aptar Food + Beverage and Aptar Pharma. Peter Pfeiffer, Aptargroup President and CEO said about this strategy: "We have always been driven to better serve our customers by enhancing our understanding of their needs and the changing markets in which they operate. This realignment will make it even easier for customers to do business with us, and we will be able to offer our full product range in each of our three segments. This next strategic step will put us in position to continue our long-term growth and lead our industry for many years to come."

 

 

The new market-focused Aptar Pharma brand

 

The Aptar Pharma organization will be implemented progressively during 2010, and will be fully operational starting in 2011. This new organization will have a much greater capacity for understanding customer needs and preferences in order to provide innovative and patient-friendly drug delivery solutions. Moreover, this organization will lead to simplified customer relations.

 

Aptar Pharma will have two divisions: Consumer Health Care, focused on drug delivery solutions adapted to over-the-counter medications; and Prescription, focused on drug delivery solutions specific to physician-prescribed medicines.

 

 

A structure dedicated to accelerating innovation

 

For over 60 years, the strategy of both Pfeiffer and Valois has been based on innovation. Their R&D organizations have been continuously expanding, and strong and sustainable links have been forged with a network of partners, which include academia, contract research as well as manufacturing organizations, inventors, design and industrial consulting companies and preferred suppliers.

 

Approximately 6% of Aptar Pharma's annual turnover is dedicated to research, development and industrialization of novel products. Aptar Pharma R&D and Marketing staff will work closer together in a global market-focused team of 200 people dedicated to satisfying customer needs.

 

Aptar Pharma also holds a strong intellectual property portfolio of over 450 patent families which can be leveraged to provide customers with protected innovative solutions.

 

 

Aptar Pharma is a part of the Aptargroup family of companies, along with Aptar Beauty + Home and Aptar Food + Beverage. Aptargroup (NYSE: ATR) is headquartered in the U.S. with facilities in North America, Europe, Asia and South America.

For more information, visit www.aptar.com

 

 

Press contact Aptar Pharma

Pierre Carlotti, VP Marketing and Communication
Dir +33 (0)1 39 17 20 01 - Fax +33 (0)1 39 58 12 98 - Email: pierre.carlotti@aptar.com

Download the press release in pdf format Clik here >>>

back

Valois Pharma, world leader in nasal and pulmonary drug delivery devices, has co-organized with the SFDA (Chinese State Food and Drug Administration) training centre, through Aptar Pharma Asia, the first Chinese training session on HFA pMDI d...

read more

Valois Pharma, world leader in nasal and pulmonary drug delivery devices, has co-organized with the SFDA (Chinese State Food and Drug Administration) training centre, through Aptar Pharma Asia, the first Chinese training session on HFA pMDI development, held in Shanghai on October 27th and 28th 2009.

 

Transition from CFC to HFA propellant: a complex issue for the pMDI industry Production of CFCs (chlorofluorocarbon), which deplete the ozone layer, was banned by the developed nations in 1996, in accordance with the 1987 Montreal Protocol. However an "essential use exemption" was granted to the pharmaceutical industry, notably for pMDI manufacture, to allow replacement products using HFA to be brought to market. As there are differences in physico-chemical properties between the two propellants, moving to HFA meant that both the drug formulation and the components of pressurized inhalers, and in particular metering valves and elastomer gaskets, had to be completely redesigned. China is currently organizing this transition from CFC to HFA pMDIs.

 

A head start for Valois Pharma

Valois Pharma was ahead of the game in gaining expertise in HFA formulations from the early 1990s, especially about the way that they interact with metering valve components. Combining in-house development and manufacturing of elastomer gaskets with the deployment of a dedicated HFA valve development team (internally managing component design, analytical tests, control of extractible materials and compatibility tests) has allowed the company to become world leader in this segment.

 

Sharing expertise for the first Chinese training on pMDI development

The two-day training session was co-organised with the SFDA training center. The SFDA is the State Chinese regulatory body in charge of supervising development, approval, manufacturing, sale and use of foodstuffs and drugs. The session was dedicated to pMDI HFA formulation development and pMDI quality controls during filling and production processes. About 60 delegates attended 13 presentations given by highly respected experts, who included:

 

• Mr. Wang Ping, SFDA: "2010 Chinese pharmacopie-inhaler standard update"

• Mr. Sunhuimin, SFDA: "pMDI HFA134a quality standard in China"

• Dr. Chenguiliang, SFDA: "The quality control and measurement during pMDI production and finished product"

• Chris Baron, Valois Pharma, Associate Director Business Development Pulmonary: "pMDI HFA formulation patents / Importance of valves and their elastomer gaskets within pMDIs"

• Dr. Gerallt Williams, Valois Pharma Director Laboratory Services: "HFA pMDIs - some product development challenges/ pMDI in-vitro testing"

• Dr Xianming Zeng, TEVA Global Respiratory R&D Director: "Next challenge in respiratory drugs development"

• Dr. Youyizhong, Professor and doctor at Changzhou N°1 Hospital: "The situation of pMDI in China and some good advice on pMDI development"

 

A significant investment by Valois Pharma / Aptar Pharma in China

The training session was a great success, as it built on the significant industrial investment made by Valois Pharma in China through Aptar Pharma Asia, which was established in Suzhou in 1996. Today there are more than 220 Aptar Pharma Asia employees at the 4,500 sqm² factory in China, manufacturing and selling, among others, Valois Pharma brand metering valves for pressurized inhalers. Valois Pharma is a recognized market leader in China and continues to expand its activity, leveraging an in-depth network of local partners to forge strong links with a wide range of local players in China, including those in research, industry, academia and regulating bodies.

 

 

Valois Pharma, a division of Valois S.A.S, specializes in nasal and pulmonary drug delivery technologies with a broad product range that also provides solutions for other drug delivery routes such as buccal/sub-lingual, throat and dermal/transdermal.

 

Valois S.A.S., founded in 1947, is a world leader in the design, development and manufacture of proprietary spray, aerosol and alternative dispensing systems for the Pharmaceutical, Perfumery and Cosmetics markets. Valois S.A.S. is a wholly owned subsidiary of AptarGroup, Inc., a publicly traded company listed on the New York Stock Exchange (NYSE: ATR).

Download the press release in pdf format Clik here >>>

back

World leader in nasal and pulmonary drug delivery devices, Valois Pharma worked closely with Nycomed to develop the spray device which allows fentanyl to be delivered intranasally for the first time to cancer patients suffering from breakthro...

read more

World leader in nasal and pulmonary drug delivery devices, Valois Pharma worked closely with Nycomed to develop the spray device which allows fentanyl to be delivered intranasally for the first time to cancer patients suffering from breakthrough pain. As well as being noninvasive and easy-to-use, fentanyl delivered by nasal spray has fast onset of action.

 

A new step forward in systemic drug delivery via the nasal route

Estimated at 2 billion dollars in 2008, the world market for systemic drug delivery by the nasal route has seen strong growth in the last few years, with the launch of products such as those containing calcitonine for osteoporosis, desmopressine for enuresis and triptans for migraine attacks. Now Nycomed's Instanyl® provides treatment for breakthrough pain in adults already receiving maintenance opioid therapy for chronic cancer pain. These episodes of moderate to severe pain, which often are difficult to anticipate, can now be managed by patients themselves.

 

Systemic drug delivery by the nasal route has a number of advantages. After being sprayed into the nasal cavity and absorbed by the nasal mucosa, the medication enters the vascular system directly allowing the active ingredient to take effect rapidly. In addition, because it is easy to use, delivery by the nasal route allows the patient to have autonomous control over the treatment.

 

The VP7 spray pump - making drug delivery easier and improving patient comfort

Valois Pharma's high-performance VP7 spray pump is widely used in drug delivery for both systemic and local treatment. For Instanyl®, Nycomed chose the VP7D version, which is designed to be used with preservative-free medication. The pump is fitted with a nasal actuator of ergonomic design that is comfortable to use. The VP7 range is recognized globally for its comfort of use by patients as well as for its total security coupled with excellent dose

accuracy and spray performance.

 

Instanyl® is a registered trademark of Nycomed

 

 

Valois Pharma, a division of Valois S.A.S, specializes in nasal and pulmonary drug delivery technologies with a broad product range that also provides solutions for other drug delivery routes such as buccal/sub-lingual, throat and dermal/transdermal.

 

Valois S.A.S., founded in 1947, is a world leader in the design, development and manufacture of proprietary spray, aerosol and alternative dispensing systems for the Pharmaceutical, Perfumery and Cosmetics markets. Valois S.A.S. is a wholly owned subsidiary of AptarGroup, Inc., a publicly traded company listed on the New York Stock Exchange (NYSE: ATR).

Download the press release in pdf format Clik here >>>

back

In association with the Indian Pharmaceutical Association, Pfeiffer and Valois Pharma, world leaders in nasal and pulmonary drug delivery devices, co-organized, through Aptar Pharma India, the Fourth International Symposium on Nasal and Pulmo...

read more

In association with the Indian Pharmaceutical Association, Pfeiffer and Valois Pharma, world leaders in nasal and pulmonary drug delivery devices, co-organized, through Aptar Pharma India, the Fourth International Symposium on Nasal and Pulmonary Drug Delivery, held in Mumbai, India, on September 17th and 18th, 2009.

 

Regulatory Challenges, a topical theme for this mature Indian conference

The first such Indian scientific conference tailored specifically to Nasal and Pulmonary Drug Delivery was held in 1999. Now a mature event, this year's symposium saw more than 150 paying delegates attending fifteen presentations over the two days, with major participation of scientists and technical experts from India's pharmaceutical industry and academia. Speakers included globally-recognized international experts such as Prof. Richard Dalby, from Maryland University in the U.S. and Jag Shur from the University of Bath in the U.K.

 

This year's event focused on Regulatory Challenges, as the Indian Pharma Industry has shown great interest over the years in introducing drug products to highly regulated markets like the US and Europe.

 

A major scientific contribution from Pfeiffer and Valois Pharma

The program was structured into three sessions: podium presentations and scientific posters covering Pulmonary (pMDIs and DPIs) and Nasal (Spray) Drug Delivery; workshops featuring research innovation and practical sessions; a lecture session providing an insight into Regulatory Challenges (formulation development, leachables and extractables, current regulatory device challenges, dossier submissions).

 

Four experts from Valois Pharma and Pfeiffer gave lectures and facilitated workshops :

• Guillaume Brouet, Valois Pharma Director Business Development Pulmonary: "Advances in the development of components for portable inhalers"

• Hervé Pacaud, Valois Pharma Director, Business Development Pumps: "Rx nasal market and new trends in nasal devices"

• Dr Gerallt Williams, Valois Pharma Director, Laboratory Services: "Current Regulatory Device Challenges: a Perspective".

• Matthias Birkhoff, Pfeiffer Pharma Division Vice-President Marketing "New technologies in Liquid Drug Delivery: Preservative Free Ophthalmic Systems"

 

The Valois Pharma presentations are available on the Valois Pharma website:

www.valois.com/pharma/en/publication/publication.php

 

A significant investment by Pfeiffer and Valois Pharma in India

Pfeiffer and Valois Pharma have been operating in India for the last ten years and have been working closely with the Indian Pharmaceutical Association to make this symposium a success. Pfeiffer and Valois Pharma are now organized under the name of Aptar Pharma India. Pfeiffer and Valois Pharma are the recognized market leaders in India for both pulmonary and nasal drug delivery devices.

 

Pfeiffer and Valois Pharma continue to expand their activity, leveraging an in-depth network of local partners to forge strong links with a wide range of players in India, including those in research, industry, academia and regulating bodies.

 

Jointly organizing this 4th symposium in India is part of Pfeiffer and Valois Pharma's global strategy to promote and develop nasal and pulmonary drug delivery technology and expertise internationally.

 

 

Pfeiffer and Valois Pharma, a division of Valois SAS, specialize in inhalation drug delivery technologies with a broad range of innovative products and services. Pfeiffer and Valois S.A.S. are wholly owned subsidiaries of AptarGroup, Inc., a publicly traded company listed on the New York Stock Exchange (NYSE: ATR).

Download the press release in pdf format Clik here >>>

back

RDD® Europe 2009 brought together pulmonary and nasal drug delivery experts from 30 countries for a unique exchange of knowledge and expertise.

read more

RDD® Europe 2009 brought together pulmonary and nasal drug delivery experts from 30 countries for a unique exchange of knowledge and expertise.

 

(25 May, 2009) – From 19 to 22 May, 430 participants interested in pulmonary and nasal drug delivery attended the Respiratory Drug Delivery Europe 2009 symposium in Lisbon. During this intensive conference, leading experts presented the latest research and innovations in this dynamic field. The organisers were delighted by the high quality science presented and the unexpectedly large number of delegates who attended despite the current economic downturn.

 

Feedback from participants also confirmed that RDD® Europe 2009 continues to enhance its reputation as one of the leading international scientific forums for academic, industrial and regulatory scientists involved in the research, development, delivery and commercialization of pulmonary and nasal drug products.

 

 

Unique mix of innovation, new ideas and real news

 

"RDD meetings continue to provide the highest quality in technical and scientific content covering our area of drug delivery. The unique mix of innovation and real news at this symposium is exceptional and rare. The organisers combine attention to detail with experience in the field to create opportunities for learning, debate and networking," said David Morton, Senior Lecturer at the Monash Institute of Pharmaceutical Sciences. A panel of invited international speakers addressed topics as diverse as the 'Expansion of Local and Systemic Therapies', 'Controlling Critical Quality Attributes during Manufacture', 'Powder Inhaler Design', 'Advances in Nasal Drug Delivery' and 'Assessing Critical Powder Properties'. Animated debate occurred around key questions associated with regulatory approval of inhalation devices.

 

 

Comprehensive and interactive program

 

Expanded workshop sessions showcased research innovations, practical advice and current regulatory thinking. RDD delegates selected which of 12 interactive workshop demonstrations by technology and services providers they wanted to attend. Podium and workshop presentations were augmented by scientific posters and a technology exhibition which ran throughout the symposium and covered all aspects of regulatory science, formulation development, new research methods and advanced drug delivery technologies. A total of 44 ingredient, device and equipment designers, plus

component and service suppliers from 11 countries presented their latest products and systems. A participant from the nebuliser workshop commented, "The workshop was very well constructed and provided an excellent overview regarding the regulatory situation, stimulating the required level of debate in the key areas."

 

 

Next Meeting, RDD 2010, Orlando, Florida

 

RDD Europe 2009 was jointly organized by RDD Online®, Pfeiffer and Valois Pharma. Based on the success of the Lisbon meeting, this team will host RDD Europe 2011. "Over 700 participants, 100 poster presenters and 75 exhibitors are expected to converge on Orlando, April 25-29 for Respiratory Drug Delivery 2010. In this vibrant field new inventions and discoveries arise continuously, so there's plenty to keep us busy between European meetings," commented one member of the US organizing committee.

 

RDD Online

RDD Online manages the organization of Respiratory Drug Delivery meetings in the US, and partners with Pfeiffer and Valois Pharma to run RDD meetings in Europe. Other RDD Online services available at www.rddonline.com include providing scientific and technical publications, web-based training, and recruiting services of interest to companies active in pulmonary and nasal drug delivery.

 

Pfeiffer and Valois Pharma

Valois Pharma, a division of Valois S.A.S., and Pfeiffer are world leaders in nasal and pulmonary drug delivery technologies with a broad range of innovative drug delivery devices, technologies and services. Pfeiffer and Valois S.A.S. are wholly owned subsidiaries of AptarGroup, Inc., a publicly traded company listed on the New York Stock Exchange (NYSE: ATR).

Download the press release in pdf format Clik here >>>

back

For World Asthma Day, Valois Pharma is unveiling the results of a clinical study with patients suffering from asthma and chronic obstructive pulmonary disease (COPD) using its proprietary Dry Powder Inhaler Prohaler®.

read more

For World Asthma Day, Valois Pharma is unveiling the results of a clinical study with patients suffering from asthma and chronic obstructive pulmonary disease (COPD) using its proprietary Dry Powder Inhaler Prohaler®.

 

The dry powder inhaler, an innovative drug delivery device contributing to the treatment of asthma

According to the WHO, there are 300 million asthma sufferers worldwide. Asthma is a serious global health problem, and is still under-diagnosed and under-treated. Today, the majority of respiratory treatments are via the pulmonary route, using either Metered Dose Inhalers (MDIs) or more recent Dry Powder Inhalers (DPIs). Patients find DPIs easier to use because they eliminate the problem of synchronization between actuation and inhalation. And as DPIs do not contain propellant, they are more environmentally-friendly.

 

Prohaler® technology, a patient-centric design approach

To make sure Prohaler® would be intuitive and easy-to-use, Valois Pharma placed the patient at the centre of the development process from the start of the project in 2004. An initial set of studies was carried out with a focus on patient handling of the device. Results publicized in June 2008 confirmed that Prohaler® was easy to handle and intuitive to use. Three simple steps are all it takes for a patient to use Prohaler®: open the device, inhale, and close it. Inhaling triggers the release of a dose of medication. A dose counter reminds the patient how many doses are left in the device.

 

The next step was to take these investigations further by understanding the patient/device interface during inhalation and verifying that all the necessary conditions were met for the correct dose of medication to be administered. A major hospital-based study was carried out from December 2007 to April 2009 at the CHRU in Tours, France, led by Professor Patrice Diot, an eminent respiratory physician and President of ISAM (the International Society for Aerosols in Medicine), and Dr. Steve Newman, an expert in inhaled dosage forms, founder of Pharmaceutical Profiles Ltd and a consultant with a worldwide reputation. 60 patients suffering from asthma or COPD took part in the two-phase study. Some of these patients had very poor lung capacity, as low as 30% of that of a normal healthy person. The results of the study showed that all the patients, regardless of how ill they were, were able to trigger the device and inhale enough air for the medication to reach their lungs. This excellent result validated the effectiveness of the Prohaler® technology and showed that most patients would be able to correctly inhale a dose of medication.

 

Results from the first phase of the study were presented by Dr. Steve Newman at the Drug Delivery to the Lungs scientific conference held in Scotland last December. Final results from the study will be published in the coming months in an internationally scientific journal.

 

With Prohaler®, Valois Pharma, the world leader in nasal and pulmonary drug delivery devices, and partner of major pharmaceutical companies, is contributing to the enhancement of patient compliance, which will lead to improved drug effectiveness, especially in the treatment of asthma and COPD.

 

 

 

Valois Pharma, a division of Valois S.A.S, specializes in nasal and pulmonary drug delivery technologies with a broad product range that also provides solutions for other drug delivery routes such as buccal/sub-lingual, throat and dermal/transdermal.

 

Valois S.A.S., founded in 1947, is a world leader in the design, development and manufacture of proprietary spray, aerosol and alternative dispensing systems for the Pharmaceutical, Perfumery and Cosmetics markets. Valois S.A.S. is a wholly owned subsidiary of AptarGroup, Inc., a publicly traded company listed on the New York Stock Exchange (NYSE: ATR).

Download the press release in pdf format Clik here >>>

back

World leader in nasal and pulmonary drug delivery devices (spray & aerosol), Valois Pharma's new web site is now on-line. Attractive and easy-to-use, this site provides both the pharmaceutical industry and the global scientific commun...

read more

World leader in nasal and pulmonary drug delivery devices (spray & aerosol), Valois Pharma's new website is now on-line. Attractive and easy-to-use, this site provides both the pharmaceutical industry and the global scientific community with free access to highlyrelevant information and tools.

 

 

Scientific publications to support advances in research

 

Valois Pharma has been developing and globally promoting research, new technology and knowledge about nasal and pulmonary drug delivery devices over the past few decades. Each year, Valois Pharma experts are regularly invited to give presentations at major scientific conferences. Now all of these presentations are available on-line on the web site and can be downloaded in real time.

 

Valois Pharma is also providing unlimited and free access to downloadable "scientific sketches" which are designed for easy  use not only in day-to-day work but also in educational and scientific presentations. Currently three of these sketches are available, covering "airways", "nasal cavity" and "nose-to-brain". More will be made available over the next few months, as well as animations showing how drug delivery devices work, in line with the company's strategy of enabling knowledge transfer and enriching the work of the scientific community.

 

These ready-to-use tools are available under the "Scientific Materials" menu item at:  http://www.valois.com/pharma/en/publication/publication.php

 

 

An Internet databank to reinforce knowledge

A comprehensive list of the major players in nasal and pulmonary drug delivery devices is available on Valois Pharma's web site. This powerful communications tool, available to all, will facilitate both research and knowledge sharing in the community. Under the "Useful Links" menu item at  www.valois.com/pharma/en/link/link.php, there are direct links with key players including regulatory agencies and academia, as well as service providers and manufacturers for contract filling and packaging, ingredients, packaging components, and nasal and pulmonary drug delivery devices.

 

 

Two routes to key information means easy access for pharmaceutical companies

The new web site's optimized ergonomic design provides clients with two different ways to access Valois Pharma's product portfolio, making searching much easier. The first is by delivery route (nasal, pulmonary, buccal, otological, dermal and transdermal); the second is by product type (pumps for sprays and metering valves for pressurized aerosols).

Product searches are found at http://www.valois.com/pharma/en/products/product.php

 

 

 

Valois Pharma, a division of Valois S.A.S, specializes in nasal and pulmonary drug delivery technologies with a broad product range that also provides solutions for other drug delivery routes such as buccal/sub-lingual, throat and dermal/transdermal.

Valois S.A.S., founded in 1947, is a world leader in the design, development and manufacture of proprietary spray, aerosol and alternative dispensing systems for the Pharmaceutical, Perfumery and Cosmetics markets. Valois S.A.S. is a wholly owned subsidiary of AptarGroup, Inc., a publicly traded company listed on the New York Stock Exchange (NYSE: ATR).

Download the press release in pdf format Clik here >>>

back

Valois Pharma will unveil a new and innovative side-actuated device for nasal drug delivery at the upcoming Nasal Drug Delivery conference, organized by Management Forum and to be held in London on April 1st and 2nd. This easy to use device, ...

read more

Valois Pharma will unveil a new and innovative side-actuated device for nasal drug delivery at the upcoming Nasal Drug Delivery conference, organized by Management Forum and to be held in London on April 1st and 2nd. This easy to use device, designed for improved patient comfort, is highly customizable.

 

An optimized device, the fruit of many years of research and two years of development

Always listening to what the market is saying and what patients are asking for, Valois Pharma conducted a series of patient acceptance studies in the UK and the US to understand nasal spray user preferences and expectations. Valois Pharma's R&D teams worked for a number of years to deliver a patented and market-ready side-actuated device that would make nasal drug delivery easier and meet the concerns of some patients who were dissatisfi ed with classic top-actuated nasal sprays.

Ease of use and comfort : real benefits for patients

The fi rst benefi t that Valois Pharma's side-actuated device delivers is that it is easy to use. Not only for self-administration, but also for third-party administration, especially in pediatric use. Compact, ergonomically designed and intuitive to use, the device requires only moderate eff ort to actuate it. This means that it can be used by a wide range of people, from adolescents to the elderly.

 

Next, but by no means least, is patient comfort. Using the side-actuator removes any possibility of axial movement of the nozzle inside the nostril when the actuator is pressed. This eliminates any risk of the nozzle entering the nostril too deeply. Moreover there is no contact between fi ngers and nostrils which improves hygiene during treatment. In addition, the device is fi tted with a level indicator which allows the patient to easily see the amount of drug left and to replace medication early before it runs out. Finally, as the movement to actuate the device is perfectly natural, it is much easier to obtain delivery of a full dose.

 

A customizable device for the pharmaceutical industry

Valois Pharma's side-actuated nasal spray device consists of a standard actuator coupled with a customizable shell and cap. This modular design is a real market advantage for pharmaceutical companies who want to reinforce their branding with an in-house style. The current focus is on nasal delivery of Rx drugs, and in particular treatment of allergic rhinitis. However future development and improvements such as integration of a dose counter could see the device being used for systemic nasal drug delivery as well.

 

Aiming for optimal patient compliance

Valois Pharma off ers integration of its side-actuated nasal spray device, which combines ease of use with patient comfort, with Equadel®, the fi rst pump that dispenses the same dose and spray every time, regardless of how much pressure is exerted by the patient. This solution reinforces patient compliance which in turn will lead to improved drug eff ectiveness.

 

 

 

Valois Pharma, a division of Valois S.A.S, specializes in nasal and pulmonary drug delivery technologies with a broad product range that also provides solutions for other drug delivery routes such as buccal/sub-lingual, throat and dermal/transdermal.

Valois S.A.S., founded in 1947, is a world leader in the design, development and manufacture of proprietary spray, aerosol and alternative dispensing systems for the Pharmaceutical, Perfumery and Cosmetics markets. Valois S.A.S. is a wholly owned subsidiary of AptarGroup,Inc., a publicly traded company listed on the New York Stock Exchange (NYSE: ATR).

Download the press release in pdf format Clik here >>>

back

World leader in nasal and pulmonary drug delivery devices, Valois Pharma is developing expertise and expanding production capacity at its Congers, New York facility in the U.S.

read more

World leader in nasal and pulmonary drug delivery devices, Valois Pharma is developing expertise and expanding production capacity at its Congers, New York facility in the U.S.

 

"Local manufacturing": real added-value for Valois of America's clients

There are two main stages in the manufacture of nasal spray drug delivery devices (nasal pumps): precision injection molding of plastic components, and high-speed assembly of components and sub-assemblies. Until now, nasal pump components manufactured at the Congers site were molded in Europe and assembled at Congers. However, molding is now being integrated into the Congers site's manufacturing process, upstream of assembly. This will allow Valois Pharma to better meet its North American clients' business expectations and help these clients grow their own markets.

 

Local manufacturing will bring real benefits to Valois of America's clients. The gain in autonomy of the Congers nasal pump production processes will result in a more reactive supply chain, better adapted to clients' needs.

 

A significant investment by Valois Pharma in this ambitious project

Integration of molding and expansion of Valois of America's site represent a significant investment for Valois Pharma. The initial phase of the project, which started at the end of 2008 and will be completed at the end of 2009, includes the creation of a molding workshop, the construction of a new ISO 7 cleanroom, and the acquisition of injection presses. The second phase of the project will see installation of additional manufacturing capacity to cope with expected market growth.

 

Overall, the scale-up is expected to last 3 years with completion in 2011. This expansion will create an

estimated 30 new jobs.

 

The industrial expansion at Valois of America's Congers site is part of Valois Pharma's international strategy to

continuously develop and modernize its 4 manufacturing facilities: Congers in the U.S., Le Vaudreuil - Val de

Reuil in France, Lugano in Switzerland and Suzhou in China.

 

 

Valois Pharma, a division of Valois S.A.S, specializes in nasal and pulmonary drug delivery technologies with a

broad product range that also provides solutions for other drug delivery routes such as buccal/sub-lingual, throat

and dermal/transdermal.

 

Valois S.A.S., founded in 1947, is a world leader in the design, development and manufacture of proprietary spray, aerosol and alternative dispensing systems for the Pharmaceutical, Perfumery and Cosmetics markets. Valois S.A.S. is a wholly owned subsidiary of AptarGroup, Inc., a publicly traded company listed on the New York Stock Exchange (NYSE: ATR).

Download the press release in pdf format Clik here >>>

back